ATAI jumps as White House executive order boosts psychedelic-drug optimism

AtaiBeckley (ATAI) is up 27.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a broad rally in psychedelic-focused biotech stocks after a new U.S. executive order directed federal health agencies to accelerate research coordination and reviews for certain psychedelic-related therapies. ATAI is often treated as a bellwether for the group, so the policy headline likely triggered momentum buying and a sector “re-rating” narrative.

Details:

A presidential executive order (dated April 18, 2026) directed agencies including HHS, FDA, and VA to improve data-sharing and speed evaluation pathways for treatments aimed at serious mental illness, increasing expectations for faster development timelines across the space.

The order also highlighted expanded federal attention to psychedelics (including ibogaine) and broader research facilitation, which can lift sentiment for companies developing psychedelic-inspired mental health drugs.

ATAI’s pipeline exposure to psychedelic-based programs makes it a direct beneficiary in investor perception when U.S. policy signals become more supportive, even if the order does not change any single ATAI program overnight.

Today’s outsized percentage gain also suggests short-term positioning and risk-on flows into smaller-cap biotech, where policy headlines can amplify moves.

Sources:

The White House, Associated Press, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ATAI Insider Trading Activity

$ATAI insiders have traded $ATAI stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ATAI stock by insiders over the last 6 months:

KEVIN JAMES CRAIG (Chief Medical Officer) sold 100,000 shares for an estimated $355,000
COSMO FEILDING-MELLEN sold 39,594 shares for an estimated $154,377

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive ATAI Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ATAI Hedge Fund Activity

We have seen 72 institutional investors add shares of $ATAI stock to their portfolio, and 66 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS GROUP AG removed 7,677,289 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,400,112
DEEP TRACK CAPITAL, LP added 4,677,289 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,130,112
BLACKROCK, INC. added 2,808,808 shares (+63836.5%) to their portfolio in Q4 2025, for an estimated $11,488,024
FORESITE CAPITAL MANAGEMENT VI LLC added 2,750,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,247,500
RTW INVESTMENTS, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,180,000
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,936,267 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $7,919,332
AMERIPRISE FINANCIAL INC added 1,735,252 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,097,180

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ATAI Analyst Ratings

Wall Street analysts have issued reports on $ATAI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026

To track analyst ratings and price targets for $ATAI, check out Quiver Quantitative's $ATAI forecast page.

$ATAI Price Targets

Multiple analysts have issued price targets for $ATAI recently. We have seen 6 analysts offer price targets for $ATAI in the last 6 months, with a median target of $15.5.

Here are some recent targets:

Sumant Kulkarni from Canaccord Genuity set a target price of $15.0 on 04/20/2026
Eddie Hickman from Guggenheim set a target price of $16.0 on 04/17/2026
David Hoang from Deutsche Bank set a target price of $12.0 on 03/27/2026
Patrick R. Trucchio from HC Wainwright & Co. set a target price of $25.0 on 03/17/2026
Ami Fadia from Needham set a target price of $14.0 on 03/09/2026
Justin Walsh from Jones Trading set a target price of $16.0 on 12/23/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.